相似文献
1
Using monoamine oxidase type B inhibitors in Parkinson's disease.
BMJ. 2004 Sep 11;329(7466):581-2. doi: 10.1136/bmj.329.7466.581.
2
Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.
Expert Rev Neurother. 2005 Nov;5(6):811-21. doi: 10.1586/14737175.5.6.811.
3
MAO-B inhibitors for the treatment of Parkinson's disease.
Mov Disord. 2002;17 Suppl 4:S38-44. doi: 10.1002/mds.5559.
4
Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease.
Expert Rev Neurother. 2009 Aug;9(8):1233-50. doi: 10.1586/ern.09.68.
5
Future therapies for Parkinson's disease.
Neurol Clin. 2004 Oct;22(3 Suppl):S149-66. doi: 10.1016/j.ncl.2004.05.005.
6
L-dopa and (-)-deprenil in the treatment of Parkinson's disease: a long-term study [proceedings].
Br J Pharmacol. 1976 Nov;58(3):423P-424P.
7
Neuroprotection for Parkinson's disease: prospects and promises.
Ann Neurol. 2003;53 Suppl 3:S1-2. doi: 10.1002/ana.10566.
8
[On the treatment of Parkinson's syndrome with monoamine oxidase inhibitors alone and in combination with L-dopa].
Praxis. 1965 Nov 18;54(46):1373-7.
9
10
MAO-B inhibitors in Parkinson's disease.
Adv Neurol. 1993;60:666-71.
引用本文的文献
1
NLRP3 inflammasome and glia maturation factor coordinately regulate neuroinflammation and neuronal loss in MPTP mouse model of Parkinson's disease.
Int Immunopharmacol. 2020 Jun;83:106441. doi: 10.1016/j.intimp.2020.106441. Epub 2020 Apr 4.
2
Neuroprotective effect of curcuminoids against inflammation-mediated dopaminergic neurodegeneration in the MPTP model of Parkinson's disease.
J Neuroimmune Pharmacol. 2012 Sep;7(3):609-18. doi: 10.1007/s11481-012-9363-2. Epub 2012 Apr 21.
3
Alternatives to levodopa in the initial treatment of early Parkinson's disease.
Drugs Aging. 2005;22(9):731-40. doi: 10.2165/00002512-200522090-00002.
本文引用的文献
1
Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients.
BMJ. 2004 Sep 11;329(7466):593. doi: 10.1136/bmj.38184.606169.AE. Epub 2004 Aug 13.
2
Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review.
Lancet. 2002 Oct 5;360(9339):1037-43. doi: 10.1016/s0140-6736(02)11138-x.
3
MAO-B inhibitors for the treatment of Parkinson's disease.
Mov Disord. 2002;17 Suppl 4:S38-44. doi: 10.1002/mds.5559.
4
Treatment interventions for Parkinson's disease: an evidence based assessment.
Lancet. 2002 May 4;359(9317):1589-98. doi: 10.1016/S0140-6736(02)08520-3.
5
Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial.
Neurology. 2001 Nov 13;57(9):1687-94. doi: 10.1212/wnl.57.9.1687.
6
Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry.
BMJ. 1998 Apr 18;316(7139):1191-6. doi: 10.1136/bmj.316.7139.1191.
7
Mortality in DATATOP: a multicenter trial in early Parkinson's disease. Parkinson Study Group.
Ann Neurol. 1998 Mar;43(3):318-25. doi: 10.1002/ana.410430309.
8
Bias in meta-analysis detected by a simple, graphical test.
BMJ. 1997 Sep 13;315(7109):629-34. doi: 10.1136/bmj.315.7109.629.
9
Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom.
BMJ. 1995 Dec 16;311(7020):1602-7. doi: 10.1136/bmj.311.7020.1602.
10
Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology?
J Neurol Neurosurg Psychiatry. 1995 Mar;58(3):293-9. doi: 10.1136/jnnp.58.3.293.
Zotero 插件